PD Dr. med. Heinrich Schulte-Baukloh - Beckenboden, Berlin - Publikationen

Publikationen zum Thema Beckenboden:

1: Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J.
Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2,
and P2X3 receptors in children and adolescents who have neurogenic detrusor
overactivity: a single-blind study. Urology. 2013 May;81(5):1052-7. doi:
10.1016/j.urology.2012.12.021. Epub 2013 Feb 15. PubMed PMID: 23419459.

2: Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B,
Thompson C, Li D, Haag-Molkenteller C. Long-term efficacy and safety of
onabotulinumtoxinA in patients with urinary incontinence due to neurogenic
detrusor overactivity: an interim analysis. Urology. 2013 Mar;81(3):491-7. doi:
10.1016/j.urology.2012.11.010. Epub 2013 Jan 3. PubMed PMID: 23290144.

3: Neuhaus J, Schulte-Baukloh H, Stolzenburg JU, Speroni di Fenizio P, Horn LC,
Rüffert H, Hartenstein S, Burger M, Schulze M, Schwalenberg T. Individual
receptor profiling as a novel tool to support diagnosis of bladder pain
syndrome/interstitial cystitis (BPS/IC). World J Urol. 2012 Oct;30(5):693-700.
doi: 10.1007/s00345-011-0774-0. Epub 2011 Oct 4. PubMed PMID: 21969132.

4: Schulte-Baukloh H, Herholz J, Bigalke H, Miller K, Knispel HH. Results of a
BoNT/A antibody study in children and adolescents after onabotulinumtoxin A
(Botox®) detrusor injection. Urol Int. 2011;87(4):434-8. doi: 10.1159/000331726.
Epub 2011 Sep 28. PubMed PMID: 21967991.

5: Schulte-Baukloh H, Mürtz G, Heine G, Austin P, Miller K, Michael T, Strugala
G, Knispel HH. Urodynamic effects of propiverine in children and adolescents with
neurogenic bladder: results of a prospective long-term study. J Pediatr Urol.
2012 Aug;8(4):386-92. doi: 10.1016/j.jpurol.2011.07.014. Epub 2011 Sep 9. PubMed
PMID: 21907623.

6: Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta
P. Urodynamic results and clinical outcomes with intradetrusor injections of
onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in
idiopathic overactive bladder. Neurourol Urodyn. 2011 Apr;30(4):556-62. doi:
10.1002/nau.21021. Epub 2011 Feb 23. PubMed PMID: 21351127.

7: Schulte-Baukloh H. [Botulinum toxin (BoNT) : Short form of a European
consensus panel report regarding recommendations on the use of botulinum toxin in
the treatment of lower urinary tract disorders and pelvic floor dysfunctions].
Urologe A. 2010 Jan;49(1):56-63. doi: 10.1007/s00120-009-2140-z. German. PubMed
PMID: 19876612.

8: Madersbacher H, Mürtz G, Alloussi S, Domurath B, Henne T, Körner I, Niedeggen
A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G.
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in
children and adolescents: results of a multicentre observational cohort study.
BJU Int. 2009 Mar;103(6):776-81. doi: 10.1111/j.1464-410X.2008.08093.x. Epub 2008
Oct 24. PubMed PMID: 19007380.

9: Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A,
Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ; European Consensus Panel.
Recommendations on the use of botulinum toxin in the treatment of lower urinary
tract disorders and pelvic floor dysfunctions: a European consensus report. Eur
Urol. 2009 Jan;55(1):100-19. doi: 10.1016/j.eururo.2008.09.009. Epub 2008 Sep 17.
Review. PubMed PMID: 18823697.

10: Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, Knispel
HH. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy
failure. Int J Urol. 2008 May;15(5):407-15; discussion 415. doi:
10.1111/j.1442-2042.2008.02016.x. PubMed PMID: 18452456.

11: Schulte-Baukloh H, Zurawski TH, Knispel HH, Miller K, Haferkamp A, Dolly JO.
Persistence of the synaptosomal-associated protein-25 cleavage product after
intradetrusor botulinum toxin A injections in patients with myelomeningocele
showing an inadequate response to treatment. BJU Int. 2007 Nov;100(5):1075-80.
Epub 2007 Sep 3. PubMed PMID: 17784887.

12: Schulte-Baukloh H, Bigalke H, Heine G, Pape D, Stuerzebecher B, Miller K,
Knispel HH. Antibodies against botulinum neurotoxin type A as a cause of
treatment failure after the first detrusor injection. Urology. 2007
Mar;69(3):575.e13-5. PubMed PMID: 17382174.

13: Schulte-Baukloh H, Knispel HH. Neuromodulatory therapies in female pelvic
medicine and reconstructive surgery: biological agents. BJU Int. 2006 Sep;98
Suppl 1:50-60; discussion 61. Review. PubMed PMID: 16911604.

14: Denys P, Corcos J, Everaert K, Chartier-Kastler E, Fowler C, Kalsi V, Nitti
V, Schulte-Baukloh H, Schurch B. Improving the global management of the
neurogenic bladder patient: part II. Future treatment strategies. Curr Med Res
Opin. 2006 May;22(5):851-60. Review. PubMed PMID: 16709307.

15: Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH.
Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic
detrusor overactivity in multiple sclerosis patients: an objective and subjective
analysis. Neurourol Urodyn. 2006;25(2):110-5. PubMed PMID: 16470519.

16: Denys P, Corcos J, Everaert K, Chartier-Kastler E, Fowler C, Kalsi V, Nitti
V, Schulte-Baukloh H, Schurch B. Improving the global management of the
neurogenic bladder patient: part I. The complexity of patients. Curr Med Res
Opin. 2006 Feb;22(2):359-65. PubMed PMID: 16466608.

17: Schulte-Baukloh H, Mürtz G, Henne T, Michael T, Miller K, Knispel HH.
Urodynamic effects of propiverine hydrochloride in children with neurogenic
detrusor overactivity: a prospective analysis. BJU Int. 2006 Feb;97(2):355-8.
PubMed PMID: 16430646.

18: Schulte-Baukloh H, Knispel HH, Stolze T, Weiss C, Michael T, Miller K.
Repeated botulinum-A toxin injections in treatment of children with neurogenic
detrusor overactivity. Urology. 2005 Oct;66(4):865-70; discussion 870. PubMed
PMID: 16230156.

19: Schulte-Baukloh H, Weiss C, Stolze T, Herholz J, Stürzebecher B, Miller K,
Knispel HH. Botulinum-A toxin detrusor and sphincter injection in treatment of
overactive bladder syndrome: objective outcome and patient satisfaction. Eur
Urol. 2005 Dec;48(6):984-90; discussion 990. Epub 2005 Jul 18. PubMed PMID:

20: Schulte-Baukloh H, Weiss C, Schobert J, Stolze T, Stürzebecher B, Knispel HH.
[Subjective patient satisfaction after injection of botulinum-a toxin in detrusor
overactivity]. Aktuelle Urol. 2005 Jun;36(3):230-3. German. PubMed PMID:

21: Schulte-Baukloh H, Weiss C, Stolze T, Stürzebecher B, Knispel HH. Botulinum-A
toxin for treatment of overactive bladder without detrusor overactivity:
urodynamic outcome and patient satisfaction. Urology. 2005 Jul;66(1):82-7. PubMed
PMID: 15992872.

22: Schulte-Baukloh H, Thalau F, Stürzebecher B, Knispel HH. Pubovaginal bone
anchor fixation with polyethylene versus fascia lata slings in the treatment of
female stress incontinence: sling material and processing are predominant factors
in success. Can J Urol. 2005 Apr;12(2):2581-7. PubMed PMID: 15877939.

23: Schulte-Baukloh H, Knispel HH. A minimally invasive technique for outpatient
local anaesthetic administration of intradetrusor botulinum toxin in intractable
detrusor overactivity. BJU Int. 2005 Feb;95(3):454. PubMed PMID: 15679820.

24: Schulte-Baukloh H, Stürzebecher B, Blömers F, Fleck H, Knispel HH. Orandi
one-stage urethroplasty using the subcutaneous pedicle graft modification of
Raatzsch--long-term results. Scand J Urol Nephrol. 2004;38(4):321-5. PubMed PMID:

25: Schulte-Baukloh H, Knispel HH. [Botulinum toxin in urology. An inventory].
Urologe A. 2004 Aug;43(8):963-75. Review. German. PubMed PMID: 15278202.

26: Schulte-Baukloh H, Michael T, Stürzebecher B, Knispel HH. Botulinum-a toxin
detrusor injection as a novel approach in the treatment of bladder spasticity in
children with neurogenic bladder. Eur Urol. 2003 Jul;44(1):139-43. PubMed PMID:

27: Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the
treatment of high leak-point pressure in children with neurogenic bladder. BJU
Int. 2002 Nov;90(7):716-20. PubMed PMID: 12410754.

28: Schulte-Baukloh H, Knispel HH, Michael T. Botulinum-A toxin in the treatment
of neurogenic bladder in children. Pediatrics. 2002 Aug;110(2 Pt 1):420-1. PubMed
PMID: 12165609.

29: Schulte-Baukloh H, Michael T, Schobert J, Stolze T, Knispel HH. Efficacy of
botulinum-a toxin in children with detrusor hyperreflexia due to
myelomeningocele: preliminary results. Urology. 2002 Mar;59(3):325-7; discussion
327-8. PubMed PMID: 11880062.